NeuroOne Medical Technologies Corporation, trading on Nasdaq as NMTC, will conduct a virtual investor webinar on Thursday, March 12, 2026, at 11:30 a.m. Eastern Time. The company, which specializes in medical technologies for neurological disorders, stated that management will use the event to deliver a corporate update, outline growth strategies, and provide details on its platform technologies, applications, and commercialization efforts. A question-and-answer session will follow the presentation.
To participate in the webinar, investors can dial in using the U.S. toll-free number 888-506-0062 or the international number 973-528-0011, with participant access code 358063. Alternatively, a live webcast will be available at https://www.webcaster4.com/Webcast/Page/2914/53635. The company advises joining at least five minutes early to ensure timely access. A replay of the call will be accessible through Thursday, March 26, 2026, by calling 877-481-4010 in the United States or 919-882-2331 internationally, using replay passcode 53635. The webcast replay will also be available via the same link until that date.
NeuroOne focuses on transforming surgical diagnosis and treatment for neurological conditions through its minimally invasive, high-definition electrode technology platform. The company has four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System for the brain, and OneRF® Trigeminal Nerve Ablation System. These technologies aim to reduce hospitalizations and surgical procedures, lower healthcare costs, and enhance patient outcomes by integrating diagnostic and therapeutic functions. Additionally, NeuroOne is engaged in research and development for drug delivery and spinal cord stimulation programs, as detailed on its website at https://nmtc1.com.
The implications of this announcement are significant for investors, the medical technology industry, and patients worldwide. By hosting this webinar, NeuroOne is positioning itself to communicate its progress and future direction, which could influence investor confidence and stock performance. For the healthcare sector, the company's technologies represent advancements in neurological care, potentially leading to less invasive treatments and better recovery rates for conditions like epilepsy or chronic pain. This aligns with broader trends toward precision medicine and cost-effective healthcare solutions. Patients suffering from neurological disorders may benefit from improved surgical options that minimize risks and recovery times, ultimately enhancing quality of life. The webinar serves as a key opportunity for stakeholders to gauge NeuroOne's trajectory and its role in addressing critical medical needs.
